Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3072 - The role of clinical characteristics in low grade gliomas in molecular era


10 Sep 2017


Poster display session


Central Nervous System Malignancies


Antonella Mura


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


A. Mura1, E. Franceschi1, S. Minichillo1, A. Mandrioli1, A. Tosoni1, A. Fioravanti1, A. Talacchi2, L. Volpin3, G. Tallini4, D. De Biase4, R. Agati5, S. Pizzolitto6, S. Bartolini1, A. Paccapelo1, A.A. Brandes1

Author affiliations

  • 1 Medical Oncology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 2 Department Of Neurological, Neuropsychological, Morphological And Movement Sciences, Section Of Neurosurgery, University of Verona, University Hospital, Verona/IT
  • 3 Neuroscience And Neurosurgery, San Bortolo Hospital, Vicenza/IT
  • 4 Department Of Biomedical And Neuromotor Sciences (dibinem), Section Of Pathology, M. Malpighi, Bellaria Hospital, University of Bologna, Bologna/IT
  • 5 Department Of Neuroradiology, Bellaria Hospital, IRCCS Institute of Neurological Sciences, Bologna/IT
  • 6 Department Of Pathology, Santa Maria della Misericordia Hospital, Udine/IT


Abstract 3072


Low grade gliomas (LGGs) are rare tumors. Molecular characterization has been recently integrated into diagnostic workup of low grade gliomas (LGG) defining specific prognostic features. Moreover, clinical factors, such as age and the extent of resection have a prognostic role in LGG. Here we report a comprehensive analysis on clinical and molecular features impacting on outcome in a large cohort of LGG.


We evaluated adult LGG patients (pts) which occurred from 1991 to 2015, who received surgery and had sufficient tissue to assess molecular biomarkers characterization. We assessed the status of IDH mutation (using PCR or NGS) 1p19q codeletion (FISH), MGMT methylation (detected with PCR).


213 consecutive LGG were included. The median age was 38 (range:18–69). Median follow up was 98.3 months, 25 pts (11.7%) underwent biopsy, 124 pts (58.2%) subtotal resection, 64 pts (30%) grosstotal resection. According to RTOG criteria 37pts (17.4%) were low-risk (


The definition of LGG outcome is complex. Both clinical and molecular factors are needed to determine prognosis and treatment strategies.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.